Christopher Pinard, DVM, DVSc, DACVIM (Oncology), is a clinician scientist and medical oncologist at Lakeshore Animal Health Partners, adjunct professor at the University of Guelph, and CEO of ANI.ML Health Inc. ANI.ML Health integrates AI and spatial computing to enhance veterinary care, launching Hachiko in 2025—a first-of-its-kind veterinary medical record summarizer. His research focuses on AI-driven biomarkers for canine and feline cancers, leveraging machine learning for comparative oncology. He explores spatial computing, 3D modelling, and AI to improve patient outcomes. Pinard has co-authored multiple AI-focused publications and is a faculty affiliate at CARE-AI. He is also a member of T-CAIREM and the International Immuno-Oncology Biomarker Working Group. He has served on the Morris Animal Foundation Osteosarcoma Scientific Advisory Board and ACVIM’s AI Task Force. He is currently the guest editor of BMC Veterinary Oncology’s special issue on AI and Informatics. His research is actively funded for next-generation AI in medicine.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related